Microsoft faces a paradox: thriving financially, yet undergoing significant layoffs. Satya Nadella acknowledged the "enigma ...

Cigna's earnings report is coming soon, so investors are on edge. Will Cigna surpass Wall Street's estimates, or will it fall ...

Thermo Fisher Scientific Inc. just made headlines with its hefty $17.6 billion acquisition of PPD, Inc., aiming to bolster ...

In a turbulent market, Blackstone Inc showcased a robust Q2 2025, with a sharp increase in assets under management (AUM) and ...

UBS remains bullish on Merck, reiterating its Buy rating with a $105 price target. This optimism follows Merck's planned $10 ...

Freemont Management S.A. just made a splash, investing $2.95 million in Salesforce. But they aren't the only ones shaking ...

Los Angeles Capital Management LLC dramatically increased its Johnson & Johnson holdings by 213.6% in Q1, now owning ...

Abbott Laboratories might just be the prescription for your portfolio. The company is sitting pretty thanks to strong ...

Seaport Res Ptn has updated its Q3 earnings forecast for Morgan Stanley, pushing the EPS estimate from $2.03 to $2.09. This ...

Visa faces a regulatory reckoning in Switzerland over interchange fees. The Swiss Competition Commission's (ComCo) actions ...

Eli Lilly's Alzheimer's drug, donanemab (Kisqali), just got a thumbs-up from the European Medicines Agency's (EMA) expert ...

UBS Group recently elevated its price target on RTX from $166.00 to $177.00, signaling a robust 14.05% potential upside, ...